1. Home
  2. ATYR vs EM Comparison

ATYR vs EM Comparison

Compare ATYR & EM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • EM
  • Stock Information
  • Founded
  • ATYR 2005
  • EM 2017
  • Country
  • ATYR United States
  • EM China
  • Employees
  • ATYR N/A
  • EM N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • EM Other Consumer Services
  • Sector
  • ATYR Health Care
  • EM Consumer Discretionary
  • Exchange
  • ATYR Nasdaq
  • EM Nasdaq
  • Market Cap
  • ATYR 535.0M
  • EM 286.5M
  • IPO Year
  • ATYR 2015
  • EM 2021
  • Fundamental
  • Price
  • ATYR $1.01
  • EM $1.34
  • Analyst Decision
  • ATYR Buy
  • EM Hold
  • Analyst Count
  • ATYR 6
  • EM 1
  • Target Price
  • ATYR $8.88
  • EM $1.25
  • AVG Volume (30 Days)
  • ATYR 14.2M
  • EM 1.9M
  • Earning Date
  • ATYR 11-06-2025
  • EM 11-26-2025
  • Dividend Yield
  • ATYR N/A
  • EM N/A
  • EPS Growth
  • ATYR N/A
  • EM N/A
  • EPS
  • ATYR N/A
  • EM N/A
  • Revenue
  • ATYR N/A
  • EM $259,541,587.00
  • Revenue This Year
  • ATYR $420.85
  • EM $3.30
  • Revenue Next Year
  • ATYR $1,919.44
  • EM $5.26
  • P/E Ratio
  • ATYR N/A
  • EM N/A
  • Revenue Growth
  • ATYR N/A
  • EM N/A
  • 52 Week Low
  • ATYR $1.00
  • EM $0.50
  • 52 Week High
  • ATYR $7.29
  • EM $1.45
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 22.22
  • EM 58.53
  • Support Level
  • ATYR $1.00
  • EM $1.34
  • Resistance Level
  • ATYR $6.50
  • EM $1.37
  • Average True Range (ATR)
  • ATYR 0.46
  • EM 0.03
  • MACD
  • ATYR -0.51
  • EM -0.00
  • Stochastic Oscillator
  • ATYR 0.83
  • EM 50.00

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About EM Smart Share Global Limited

Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.

Share on Social Networks: